AMBEV S.A. current report, Q2 FY2021

Business Context and Reporting Period

This Form 6-K filing by AMBEV S.A. covers the period from March 1, 2021, to March 31, 2021. The report was filed on April 8, 2021, and details consolidated transactions of securities and derivatives involving the company's Board of Directors, Management, and Fiscal Council in compliance with Article 11 of CVM Instruction # 358/2002.

Key Financial Metrics

The filing text does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly limited to reporting insider trading activity and equity balances for specific personnel groups.

Insider Transaction Summary (March 2021)

Group Transaction Type Securities Quantity Volume (R$)
Board of Directors Buy (Election/Stock Options) Common Shares / ADRs 222,870 R$ 0.00
Board of Directors Sell (Renounce) Common Shares 88,215 R$ 0.00
Management Buy (PSU/Stock Options) Common Shares / ADRs 328,624 R$ 393,744.89
Management Sell (Market) Common Shares 33,100 R$ 515,372.00
Fiscal Council None N/A 0 R$ 0.00

Material Changes

The filing does not provide comparative data against prior periods to determine material changes in financial performance or insider trading volume trends. It only reports the specific activity occurring within March 2021.

Guidance, Outlook, and Risks

The filing text does not contain management commentary, financial guidance, outlook, risk factors, or contingencies. The document serves solely as a regulatory disclosure of securities transactions.

Key Facts for Investor Verification

  • Transaction Nature: Most "Buy" transactions for the Board and Management were stock option exercises or restricted share deliveries (PSU) with a reported price of R$ 0.00, except for PSU deliveries to Management valued at R$ 14.21/share.
  • Market Sales: Management sold 33,100 common shares on the open market via intermediaries (Itaú Corretora and Ágora Corretora) at prices ranging from R$ 15.08 to R$ 15.61.
  • Equity Balances: Final balances for the Board of Directors were 32,367,601 Common Shares and 1,136,139 ADRs. Final balances for Management were 5,473,554 Common Shares and 563,469 ADRs.
  • Scope Limitation: This report does not reflect the company's overall financial health or operational results for the quarter.